Skip to main content
Caplight Logo









CellOrigin Biotech

CellOrigin Biotech

Private
HangzhouHealthcare & Life Scienceshttps://cell-origin.com

Last Round

Early Funding

Sep 21, 2023

Company Overview

CellOrigin Biotech is a biotechnology company that develops genetically engineered iPSC-derived immune cell therapies for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

cell therapyiPSCinduced pluripotent stem cellsoff-the-shelf therapyallogeneic cell therapyCAR-iMACCAR-iNKsolid tumor treatmentgene editingsynthetic biologyimmunotherapyoff-the-shelf medicinenext-gen CAR-Tbiotech R&Ddrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CellOrigin Biotech Comparables

Compare CellOrigin Biotech with similar companies based on industry and business-model similarity.

CellOrigin Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Neukio Biotherapeutics
86%
Qihan Biotech
86%
RocRock Biotechnology
85%

CellOrigin Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingSep 21, 2023
VC RoundMar 21, 2022
AngelJul 16, 2021

CellOrigin Biotech Investors

Notable investors and investment history

CellOrigin Biotech investors
InvestorRounds
Jifeng VenturesVC Round
Yinxinggu CapitalVC Round
Nest.BioAngel
Kunlun CapitalVC Round, Angel
Efung CapitalVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 7, 2025

    Monthly visitors increased 1574% MoM, from 19 to 318.

  • Sep 21, 2023

    Completed an early funding round.

CellOrigin Biotech Filings

Explore SEC and related filing metadata, where available.

CellOrigin Biotech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about CellOrigin Biotech's valuation, stock price, and market status.

Is CellOrigin Biotech a public or private company?

CellOrigin Biotech is a private company.

What is the current stock price of CellOrigin Biotech?

CellOrigin Biotech is a private company, so its shares have no public market price. Caplight tracks CellOrigin Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is CellOrigin Biotech worth (valuation)?

Valuation information for CellOrigin Biotech is not publicly available.

Can I buy CellOrigin Biotech stock?

CellOrigin Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was CellOrigin Biotech's last funding round?

CellOrigin Biotech's most recent funding round was Early Funding on September 21, 2023.

Who are the main investors in CellOrigin Biotech?

Key investors in CellOrigin Biotech include Jifeng Ventures, Kunlun Capital.

Will CellOrigin Biotech IPO soon?

No public IPO plans have been announced for CellOrigin Biotech.

How can I track CellOrigin Biotech secondary market activity?

Caplight tracks bids, offers, and trades in CellOrigin Biotech's shares on secondary markets.

Firmographic Details

HeadquartersHangzhou
Employee Range4
Year Founded2018
Last FundingSep 21, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?